Comparative efficacy of buparvaquone and imidocarb in inhibiting the in vitro growth of Babesia bovis
Frontiers in Pharmacology · 01.05.2024 · 15
DOI: 10.3389/fphar.2024.1407548 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 01.05.2024. Verfasst von Natalia M Cardillo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Animal Disease Research Unit, United States Department of Agriculture, Agricultural Research Service, WSU, Pullman, WA, United States. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA.
Abstract (Originalsprache)
Introduction
B. bovis is an apicomplexan parasite responsible for bovine babesiosis, a tick-borne disease with a worldwide impact. The disease remains inefficiently controlled, and few effective drugs, including imidocarb dipropionate (ID), are currently available in endemic areas. The objective of this study was to evaluate whether buparvaquone (BPQ), a drug currently used to treat cattle infected with the Babesia -related Theileria spp. parasites, could be active against Babesia parasites. Herein, we compared the effect of ID and BPQ on B. bovis growth in vitro erythrocyte culture.
Methods
We compared the effect of ID and BPQ on the culture-adapted Texas T2Bo strain of B. bovis. In vitro cultured parasites were incubated with ID and BPQ at two starting parasitemia levels (PPE), 0.2% and 1%. In vitro cultured parasites were treated with ID or BPQ at concentrations ranging from 10 to 300 nM, during 4 consecutive days. Parasitemia levels were daily evaluated using microscopic examination. Data was compared using the independent Student’s t-test. Results and discussion: Both ID and BPQ significantly inhibited ( p < 0.05) the growth of B. bovis , regardless of the initial parasitemia used. At 1% parasitemia, BPQ had lower calculated inhibitory concentration 50 (IC50: 50.01) values than ID (IC50: 117.3). No parasites were found in wells with 0.2% starting parasitemia, treated previously with 50 nM of BPQ or ID, after 2 days of culture without drugs. At 1% parasitemia, no parasite survival was detected at 150 nM of BPQ or 300 nM of ID, suggesting that both drugs acted as babesiacidals.
Conclusion
Overall, the data suggests that BPQ is effective against B. bovis and shows a residual effect that seems superior to ID, which is currently the first-line drug for treating bovine babesiosis globally.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Animal Disease Research Unit, United States Department of Agriculture, Agricultural Research Service, WSU, Pullman, WA, United States.
- Estación Experimental INTA Paraná Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Parana, Argentina.
- Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA, United States.
- Program in Individualized Medicine, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, United States.
- Oregon Health and Science University, Portland, OR, United States.
- VA Portland Healthcare System, Portland, OR, United States.
Förderung
- BLRD VA
Zitieren
APA
Cardillo, N. M., Lacy, P. A., Villarino, N. F., Doggett, J. S., Riscoe, M. K., Bastos, R. G., Laughery, J. M., Ueti, M. W., & Suarez, C. E. (2024). Comparative efficacy of buparvaquone and imidocarb in inhibiting the in vitro growth of Babesia bovis. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1407548
Vancouver
Cardillo NM, Lacy PA, Villarino NF, Doggett JS, Riscoe MK, Bastos RG, et al. Comparative efficacy of buparvaquone and imidocarb in inhibiting the in vitro growth of Babesia bovis. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1407548
BibTeX
@article{Cardillo2024,
author = {Cardillo, Natalia M and Lacy, Paul A and Villarino, Nicolas F and Doggett, J Stone and Riscoe, Michael K and Bastos, Reginaldo G and Laughery, Jacob M and Ueti, Massaro W and Suarez, Carlos E},
title = {Comparative efficacy of buparvaquone and imidocarb in inhibiting the in vitro growth of Babesia bovis},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1407548}
}
EUVIMED